First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland

Belzutifan is a new HIF-α inhibitor mainly used in two different indications: von Hippel–Lindau syndrome-associated renal cell carcinoma, haemangioblastomas and pancreatic neuroendocrine tumours, as well as sporadic advanced pre-treated renal cell carcinoma. Although efficacy has been demonstrated i...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology (Toronto) Vol. 32; no. 2; p. 64
Main Authors: Peres, Tobias, Aeppli, Stefanie, Fischer, Stefanie, Hundsberger, Thomas, Rothermundt, Christian
Format: Journal Article
Language:English
Published: Switzerland MDPI 26.01.2025
MDPI AG
Subjects:
Adult
Aged
belzutifan
Carcinoma, Renal Cell - drug therapy
Case Report
case series
Female
haemangioblastomas
HIF-α inhibitor
Humans
Hypoxia-Inducible Factor 1, alpha Subunit - antagonists & inhibitors
Indenes
Kidney Neoplasms - drug therapy
Male
Middle Aged
renal cell carcinoma
Retrospective Studies
Switzerland
von Hippel-Lindau Disease - complications
von Hippel-Lindau Disease - drug therapy
von Hippel–Lindau syndrome
Switzerland
real-world
renal cell carcinoma
HIF-α inhibitor
belzutifan
case series
von Hippel–Lindau syndrome
haemangioblastomas
ISSN:1718-7729, 1198-0052, 1718-7729
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Belzutifan is a new HIF-α inhibitor mainly used in two different indications: von Hippel–Lindau syndrome-associated renal cell carcinoma, haemangioblastomas and pancreatic neuroendocrine tumours, as well as sporadic advanced pre-treated renal cell carcinoma. Although efficacy has been demonstrated in phase II and III studies, belzutifan is still not approved in many countries. In addition, von Hippel–Lindau syndrome is a rare disease. Therefore, there is virtually no real-world experience data of belzutifan efficacy available. We aim to determine the real-world efficacy and tolerability of belzutifan in patients with von Hippel–Lindau syndrome-associated tumours and in patients with sporadic advanced tyrosine kinase- and immune checkpoint inhibitors pre-treated for renal cell carcinoma. A retrospective analysis of five patients treated with belzutifan between 2023 and 2024 at a Swiss cancer centre was conducted. In this case series, all patients consistently benefitted from belzutifan with response to treatment. This case series provides real-world evidence that belzutifan is an effective and well-tolerated treatment option for patients with von Hippel–Lindau syndrome-associated renal cell carcinoma, haemangioblastomas and sporadic advanced pre-treated renal cell carcinoma.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1718-7729
1198-0052
1718-7729
DOI:10.3390/curroncol32020064